MarketsandMarkets Real-World Evidence and Market Access Conference

WHAT TO EXPECT

Regulatory view around data quality & data standards.
Leveraging RWE for improving market access.
The adoption & role of AI & ML in clinical trials.
Real-world evidence & Digital Health - The expanded role of RWE for digital health.
Real-World Data & Advanced Analytics.
RWE to inform decision making process in rare diseases where there is lack of evidence.

Learn about the recent trends and advancements in Real-World Evidence Generation
Engage in meaningful discussion with the most prominent industry experts and decision makers from pharmaceutical and biopharmaceutical companies who will address most critical challenges in real-world data and real-world evidence space.
Opportunity to network and exchange scientific knowledge with expert speakers from leading pharmaceutical companies, global regulators and solution providers

From Pharmaceutical and Biopharmaceutical companies

Chief executives, VP’s, Directors, Global heads, Heads, Leaders, Senior Managers, Researcher, Analysts, Investigators, Scientists within the following departments-

Real-World Evidence
Real-World Data
Data Analytics
Health Economics & Outcomes Research- HEOR
Market Access/Value Access
Policy
Clinical Development & research
Clinical trial
Centre for Observational and Real-World Evidence
Epidemiology
Oncology-RWE
Pricing and Reimbursement
Medical Affairs
Pharmacovigilance
Life Science Analytics
Big data
Data Science
Bio-Statistics
Consumer Healthcare

CONFERENCE AGENDA

Registration	08:15 - 08:50
Welcome note by MarketsandMarkets	08:50 - 08:55
Opening remarks by the Chairperson Helene Vioix, Director Global Evidence & Value Development Oncology, Merck KGaA	08:55 - 09:00
Application of Real-World Evidence (RWE) in Medication and Outcomes
Patient Access to Precision Medicine Oncology	09:00 - 09:30
Maximizing the influence of RWD in cases of Rare Diseases Helene Vioix, Director Global Evidence & Value Development Oncology, Merck KGaA	09:30 - 10:00
Solution Provider Presentation - Lynx Care Dries Hens, Chief Medical Officer, Co-founder , LynxCare Shahbaz Pervaiz, Director of RWE Services, LynxCare, Inc.	10:00 - 10:30
Morning Refreshments and Poster Presentation \| One-to-One Networking Meeting	10:30 - 11:20
Population Adjusted RCTs – An Option for HTA Authorities Michael Happich, Sr Director HTA, International Markets, Eli Lilly and Company	11:20 - 11:50
Accelerate and de-risk Clinical Development & Market Access through AI-powered Real- World Disease and Care simulation. Alexandre Templier, President, Quinten Health	11:50 - 12:20
RWE in Radiology: Promises and Pitfalls Oisin Butler, Integrated Evidence Generation Lead, Bayer Radiology	12:20 - 12:50
Presentation by Davy Yeung, Managing Director and Vice President of Operations, Tailored Clinical Research Solutions	12:50 - 13:20
Lunch and Poster Presentation \| One-to-One Networking	13:20 - 14:20
Let the Data Flow – Automated Digital Data Transfer from EHRs to EDC Christian Müller, Head of Data Generation, Bayer	14:20 - 14:50
From Data to Dialogue: Elevating Science-Based Communication in Post-Approval Studies Veronika Schweighart, Co-Founder, Climedo	14:50 - 15:20
Panel Discussion: Real-world Effectiveness- Does it Matter?’ Sandeep Kiri, UCB Global Payer Value Strategy- Head of Health Economics and HTA Evidence, UCB Helene Vioix, Director Global Evidence & Value Development Oncology, Merck KGaA Michael Happich, Sr Director HTA, International Markets, Eli Lilly and Company Christian Müller, Head of Data Generation, Bayer Ivan Clement, Global Associate Director, RWE & Innovative Evidence in Neuroscience , Novartis	15:20 - 15:50
Evening Refreshments and Poster Presentation \| One-to-One Networking	15:50 - 16:30
Current Trends in Patient-Centric Clinical Research amid the Rapidly evolving Landscape Meritxell Sabidó, Director- Global Epidemiology Department, Neurology and Immunology, Merck Healthcare KgaA	16:30 - 17:00
Patient Engagement Strategy and Execution	17:00 - 17:30
Achieving Patient Diversity using RWE in Clinical Trials	17:30 - 18:00
Closing remarks by the Chairperson Helene Vioix, Director Global Evidence & Value Development Oncology, Merck KGaA	18:00 - 18:00
End of Day 1	18:00 - 18:00

Registration	08:15 - 08:50
Welcome note by MarketsandMarkets	08:50 - 08:55
Opening remarks by the Chairperson	08:55 - 09:00
Role of Real-World Evidence (RWE) in Market Access – Approach and Planning
RWE- Trends in Global Market and Network Access	09:00 - 09:30
Patient Centricity in Health Technology Assessment Remon Helmy, Senior Manager, Global Health Economics & Outcomes Research (HEOR), Alexion Pharmaceuticals	09:30 - 10:00
Solution Providers Presentation Alberto Brage, Global Key Account Manager, Savanamed	10:00 - 10:30
Morning Refreshments and Poster Presentation \| One-to-One Networking	10:30 - 11:15
RWE in HTA- What does it mean in the ‘Real World’ Sandeep Kiri, UCB Global Payer Value Strategy- Head of Health Economics and HTA Evidence, UCB	11:15 - 11:45
The Socioeconomic Impact of Medical Innovation Ahmed H. Seddik, Senior Manager, Global HEOR & RWE, Oncology, Daiichi Sankyo Europe GmbH	11:45 - 12:15
Panel Discussion - The Evolution of Registries and their Value for Patients’ Communities, Payers, and Regulators. Anila Dede, Executive Director -Medical Affairs, RW Solutions, SyneosHealth Ahmed H. Seddik, Senior Manager, Global HEOR & RWE, Oncology, Daiichi Sankyo Europe GmbH Sandeep Kiri, UCB Global Payer Value Strategy- Head of Health Economics and HTA Evidence, UCB Remon Helmy, Senior Manager, Global Health Economics & Outcomes Research (HEOR), Alexion Pharmaceuticals	12:15 - 12:45
Solution Providers Presentation	12:45 - 13:15
Lunch and Poster Presentation \| One-to-One Networking	13:15 - 14:15
Pricing Market Access Strategies Case Studies	14:15 - 14:45
Assessing Patient centered approach to value-based approach	14:45 - 15:15
Closing remarks by the chairperson	15:15 - 15:15
End of Conference	15:15 - 15:15